Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38
Benzinga Newsdesk 4 months ago
NewsInitiationAnalyst RatingsPrice Target
Leerink Partners analyst Thomas Smith initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $38.
Leerink Partners analyst Thomas Smith initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $38.